ONCY - Oncolytics Biotech Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ONCY

ONCOLYTICS BIOTECH INC.

NASDAQ

$0.54

▼ DOWN 8.63% (-0.05)

KEY STATISTICS

Market Cap$54.45 M

52w High$1.32

52w Low$0.54

Dividend Yield—

Frequency—

P/E-2.02

Volume1.08M

Shares Out.100.36M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Jared Kelly

ABOUT

SECTOR

Healthcare

WENT PUBLIC

October 5, 2001

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.—

NOV

WED

SPLIT RECORD

DATE	TYPE	RATIO
2018-05-25	Reverse	2:19

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

QQQS

0.37%

142.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

3.39%

HOLDERS

TOP 8 OF 99 · RANKED BY POSITION SIZE

Marshall Wace, Llp

745.4K sh

$708.08K

Renaissance Technologies LLC

Sandbox Financial Partners, LLC

Goldman Sachs Group Inc

208.7K sh

$292.18K

PRICE

$0.54 ▼ DOWN 8.63% (−$0.05)

OVERLAYS

About Oncolytics Biotech Inc.

http://www.oncolyticsbiotech.com ↗

Oncolytics Biotech Inc., a Calgary-based biopharma company founded in 1998, develops cancer treatments like pelareorep, and collaborates with Merck KGaA, Pfizer, and PrECOG on immunotherapies for solid tumors and breast cancer.

INDUSTRY

Biotechnology

A PRODUCT ONCOLYTICS BIOTECH INC. IS KNOWN FOR

Pelareorep

Pelareorep, Oncolytics Biotech's lead investigational immunotherapy, is in late-stage trials for cancers like breast and pancreatic, aiming to activate the immune system, and has received multiple FDA Fast Track Designations.

COMPETITORS

COMPETITOR

Oncolytics Biotech in 2025

SENTIMENT: + POSITIVE

REGULATORY · Q3-Q4 2025

Oncolytics Biotech Announces Promising Clinical Data for Pelareorep in Anal Cancer, Signaling Potential for Accelerated FDA Approval

Oncolytics Biotech reported positive clinical data from its GOBLET Cohort 4 study, showing its lead product, pelareorep, combined with atezolizumab, achieved an objective response rate of approximately 29% in patients with third-line metastatic anal cancer. This result is nearly triple the historical benchmark in a patient population with no currently FDA-approved treatments, positioning the company to pursue a registration study aimed at accelerated approval.

RESTRUCTURING · OCTOBER 2025 · IN PROGRESS

Oncolytics Biotech Initiates Strategic Redomiciliation from Canada to U.S. to Align with Operational Focus and Enhance Capital Market Access

Oncolytics Biotech has made a strategic decision to change its jurisdiction of incorporation from Alberta, Canada, to Nevada, USA. This 'Domestication' is intended to better align the company's corporate structure with its predominantly U.S.-based operations, management, shareholder base, and capital markets activities, as well as to simplify its regulatory obligations.